Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Melanoma 98Carcinoma, Non-Small-Cell Lung 32Neoplasms 22Neoplasm Metastasis 14Carcinoma, Renal Cell 13Prostatic Neoplasms 12Lung Neoplasms 12Small Cell Lung Carcinoma 10Diabetes Mellitus, Insulin-Dependent, 12 10Pancreatic Neoplasms 7Uveal Melanoma 6Skin Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Advanced Cancer 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Kidney Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Carcinoma 4Breast Neoplasms 4Various Advanced Cancer 3

Interventions

Octreotide 5Everolimus 4pasireotide 3lanreotide 3ganitumab 2gallium Ga 68 dotatate 2cabozantinib 2Nivolumab 2Erlotinib Hydrochloride 2surufatinib 1pertuzumab 1nintedanib 1ibrutinib 1fosbretabulin 1conatumumab 1cixutumumab 1carfilzomib 1arginyllysine 1aflibercept 1Temozolomide 1Sunitinib 1Somatostatin 1Random Allocation 1Ramucirumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Capecitabine 1Bevacizumab 1Axitinib 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × Ipilimumab × Clear all
NCT03420521 2024-01-09

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
9 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡